PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1427443-0	1992	Ultrastructural, immunologic and clinical follow-up of five patients with HCL treated with interferon (IFN) for more than three years.	Hydrochloric Acid	74-77	interferon alpha 1	Homo sapiens	91-107	
1427443-1	1992	BACKGROUND: Treatment results in HCl have been improved by the use of alpha-IFN, which is now the standard first-line therapy for this disease, but the mechanism of IFN action is still unclear.	Hydrochloric Acid	33-36	interferon alpha 1	Homo sapiens	76-79	
1427443-1	1992	BACKGROUND: Treatment results in HCl have been improved by the use of alpha-IFN, which is now the standard first-line therapy for this disease, but the mechanism of IFN action is still unclear.	Hydrochloric Acid	33-36	interferon alpha 1	Homo sapiens	165-168	
1427443-4	1992	METHODS: We assessed the phenotype membrane and ultrastructural changes induced in HCs by long-term alpha-IFN treatment in five pts with HCL; membrane-bound Il 2-R on PHA-stimulated PBL, the release of IL 2-R by PHA-stimulated PBL and the serum levels of s-IL 2-R were also determined in one pt.	Hydrochloric Acid	137-140	interferon alpha 1	Homo sapiens	106-109	
1427443-5	1992	RESULTS: The surface immunological phenotype, mainly the HCL-related surface antigen CD25, changed after IFN treatment, dropping from abnormally high to normal values.	Hydrochloric Acid	57-60	interleukin 2 receptor subunit alpha	Homo sapiens	85-89	
1427443-5	1992	RESULTS: The surface immunological phenotype, mainly the HCL-related surface antigen CD25, changed after IFN treatment, dropping from abnormally high to normal values.	Hydrochloric Acid	57-60	interferon alpha 1	Homo sapiens	105-108